Hudson Pacific Properties, Inc. (HPP) EPS Estimated At $0.49; Shorts at Chemocentryx (CCXI) Lowered By 1.76%

January 14, 2018 - By Linda Rogers

Analysts expect Hudson Pacific Properties, Inc. (NYSE:HPP) to report $0.49 EPS on February, 15.They anticipate $0.03 EPS change or 6.52% from last quarter’s $0.46 EPS. HPP’s profit would be $76.34 million giving it 16.77 P/E if the $0.49 EPS is correct. After having $0.50 EPS previously, Hudson Pacific Properties, Inc.’s analysts see -2.00% EPS growth. The stock decreased 1.59% or $0.53 during the last trading session, reaching $32.87. About 986,718 shares traded or 10.44% up from the average. Hudson Pacific Properties, Inc. (NYSE:HPP) has risen 20.99% since January 14, 2017 and is uptrending. It has outperformed by 4.29% the S&P500.

Chemocentryx Incorporated (NASDAQ:CCXI) had a decrease of 1.76% in short interest. CCXI’s SI was 1.87 million shares in January as released by FINRA. Its down 1.76% from 1.90 million shares previously. With 76,300 avg volume, 25 days are for Chemocentryx Incorporated (NASDAQ:CCXI)’s short sellers to cover CCXI’s short positions. The SI to Chemocentryx Incorporated’s float is 8.97%. The stock decreased 6.89% or $0.62 during the last trading session, reaching $8.38. About 102,044 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 60.64% since January 14, 2017 and is uptrending. It has outperformed by 43.94% the S&P500.

Among 3 analysts covering ChemoCentryx (NASDAQ:CCXI), 1 have Buy rating, 1 Sell and 1 Hold. Therefore 33% are positive. ChemoCentryx had 5 analyst reports since September 3, 2015 according to SRatingsIntel. JMP Securities maintained the shares of CCXI in report on Thursday, August 10 with “Buy” rating. The firm has “Sell” rating by Zacks given on Thursday, September 3. As per Tuesday, February 21, the company rating was initiated by JMP Securities. Zacks downgraded the shares of CCXI in report on Monday, September 21 to “Sell” rating. As per Tuesday, August 8, the company rating was maintained by Cowen & Co.

Investors sentiment decreased to 1.14 in 2017 Q3. Its down 0.26, from 1.4 in 2017Q2. It worsened, as 12 investors sold ChemoCentryx, Inc. shares while 23 reduced holdings. 12 funds opened positions while 28 raised stakes. 23.75 million shares or 2.21% less from 24.29 million shares in 2017Q2 were reported. Bridgeway Mngmt reported 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Smith Asset Mngmt Grp Lp accumulated 27,370 shares. Voya Investment Mgmt Limited Liability Company, a Georgia-based fund reported 15,984 shares. Proshare Advsr Ltd Liability Com invested in 0% or 29,111 shares. Manufacturers Life Ins The has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Blackrock accumulated 2.77 million shares. State Of Wisconsin Inv Board reported 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Franklin Resource Incorporated reported 2.06M shares. Deutsche Financial Bank Ag holds 0% in ChemoCentryx, Inc. (NASDAQ:CCXI) or 315,882 shares. 148 were reported by Meeder Asset Mgmt. Vanguard Group Incorporated reported 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Ing Groep Nv has 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI). Macquarie Gru has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Pennsylvania-based Nationwide Fund Advsrs has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Invesco invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI).

Since August 1, 2017, it had 0 insider buys, and 1 sale for $22,667 activity. LUCAS ROGER C sold $22,667 worth of ChemoCentryx, Inc. (NASDAQ:CCXI) on Tuesday, August 1.

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. The company has market cap of $408.67 million. The Company’s lead drug candidate is Avacopan , an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor (C5Ar), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). It currently has negative earnings. The firm also engages in developing CCX140, an inhibitor of the chemokine receptor known as CCR2 for patients with focal segmental glomerulosclerosis (FSGS), a debilitating kidney disease; Vercirnon for the treatment of patients with moderate-to-severe CrohnÂ’s diseases; CCX872, a selective inhibitor of the human CCR2 that has completed Phase I clinical trial for the treatment of pancreatic cancer; CCX507, which has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and Th17 cells for the treatment of psoriasis, rheumatoid arthritis, asthma, and multiple sclerosis.

Hudson Pacific Properties is a vertically integrated real estate firm focused on acquiring, repositioning, developing and operating high-quality office and state-of-the-art media and entertainment properties in select West Coast markets. The company has market cap of $5.12 billion. Hudson Pacific invests across the risk-return spectrum, favoring opportunities where it can employ leasing, capital investment and management expertise to create additional value. It has a 84.94 P/E ratio. Founded in 2006 as Hudson Capital, the Company went public in 2010, electing to be taxed as a real estate investment trust.

Among 11 analysts covering Hudson Pacific Properties (NYSE:HPP), 7 have Buy rating, 0 Sell and 4 Hold. Therefore 64% are positive. Hudson Pacific Properties had 28 analyst reports since August 10, 2015 according to SRatingsIntel. The rating was upgraded by Mizuho to “Buy” on Friday, July 22. The firm has “Neutral” rating by Mizuho given on Monday, March 20. On Thursday, August 27 the stock rating was initiated by Cantor Fitzgerald with “Buy”. The stock of Hudson Pacific Properties, Inc. (NYSE:HPP) earned “Overweight” rating by Morgan Stanley on Friday, September 1. DA Davidson maintained the shares of HPP in report on Friday, August 5 with “Buy” rating. Zacks upgraded Hudson Pacific Properties, Inc. (NYSE:HPP) rating on Monday, August 10. Zacks has “Hold” rating and $35 target. The stock of Hudson Pacific Properties, Inc. (NYSE:HPP) has “Overweight” rating given on Thursday, March 24 by Barclays Capital. Barclays Capital maintained the shares of HPP in report on Tuesday, July 19 with “Overweight” rating. UBS initiated Hudson Pacific Properties, Inc. (NYSE:HPP) on Monday, November 2 with “Buy” rating. The stock of Hudson Pacific Properties, Inc. (NYSE:HPP) has “Buy” rating given on Monday, January 8 by Robert W. Baird.

Investors sentiment increased to 1.24 in Q3 2017. Its up 0.13, from 1.11 in 2017Q2. It is positive, as 23 investors sold Hudson Pacific Properties, Inc. shares while 57 reduced holdings. 22 funds opened positions while 77 raised stakes. 150.22 million shares or 5.13% less from 158.35 million shares in 2017Q2 were reported. Mcf Ltd has invested 0% in Hudson Pacific Properties, Inc. (NYSE:HPP). Eagle Asset owns 160,482 shares. Hsbc Public Ltd Co has invested 0% in Hudson Pacific Properties, Inc. (NYSE:HPP). Ny State Common Retirement Fund invested in 508,427 shares or 0.02% of the stock. Japan-based Nomura Asset Limited has invested 0.04% in Hudson Pacific Properties, Inc. (NYSE:HPP). Advantus Capital Mgmt Inc has invested 0.02% in Hudson Pacific Properties, Inc. (NYSE:HPP). Moreover, Swiss Bancshares has 0.01% invested in Hudson Pacific Properties, Inc. (NYSE:HPP) for 261,050 shares. Tiaa Cref Management Limited Liability Corporation reported 0.02% stake. Goldman Sachs Gru stated it has 5.47M shares. Profund Ltd Liability Co stated it has 7,918 shares. Stoneridge Inv Prtnrs Ltd Limited Liability Company owns 15,237 shares or 0.08% of their US portfolio. Citadel Advisors Llc holds 0.07% or 2.58M shares in its portfolio. Regions Fin reported 0.01% in Hudson Pacific Properties, Inc. (NYSE:HPP). Bamco New York holds 0.05% or 312,072 shares in its portfolio. Bnp Paribas Asset Management Hldgs accumulated 294,106 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>